Moderna’s R&D game plan; 2seventy layoffs amid CAR-T slowdown; Covid vaccine boosters get thumbs up; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

This week, we debuted a refresh of our manufacturing coverage here at Endpoints News, which will be led by Anna Brown in London from now on. You can learn more about the new focus from Drew Armstrong’s note — be sure to check out her stories.

Moderna’s R&D game plan

Moderna shed some light on its mRNA strategy this week with a series of news, starting with a new alliance with Immatics focused on T cell receptors that it’s paying $120 million upfront for. During its R&D Day, the big biotech shared its ambition to launch up to 15…
Click here to view original post